Numerous inhibitory immune checkpoint genes are differentially expressed, as shown in Table 1; but, importantly, all of the genes are constitutively expressed in all tumor samples, strongly suggesting that immune checkpoint inhibitors may be effective in HS treatment, including anti-PD1, anti-CTLA4, and anti-Lag3. This evidence concerns the gene PDCD1 and neoplasm.